Schizophrenia is one of the worst diseases affecting humankind. No apology is needed that our May issue carries many papers on this syndrome, the present name of which some of us deplore and have urged the World Health Organization (WHO) to change (Henderson and Malhi, 2014; Lasalvia et al., 2015) . In describing optimal management and the evidence for this, the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Clinical Guidelines by Galletly et al. (this issue) will stand for many years to come as an eximious resource for international use. As with the recent RANZCP Clinical Guidelines for Mood Disorders (Malhi et al., 2015) , we ought to recognise and appreciate the many hundreds of person-hours taken by its 10-member writing group, in collaboration with other outstanding experts and key stakeholders, within and beyond Australia and New Zealand. With any set of Guidelines, one expects to be told what are considered the best treatments and why, whether for drugs or psychosocial methods. But these Guidelines go much further: they cover the great diversity of clinical presentations of the syndrome, medication other than antipsychotics, the emerging psychological therapies, the need to consider in depth the particular needs of women, pregnancy, older persons, the Aboriginal and Torres Strait Islander population, the Māori and now those on Australian Temporary Protection Visas. This is a document that deserves our diligent attention.
A wise physician once said that all drugs are poisons, but some have useful side effects. The antipsychotic drugs have both in abundance, yet are hugely used, faute de mieux. Stomski et al. (this issue) have looked at tools for measuring their side effects, such as might be used in clinical practice or research. They have found serious methodological deficiencies in what is available: all the tools they found are fatally flawed. This raises very interesting questions, 'Should something be done about this gap; and what benefits would a good tool bring?' Abnormalities at the cellular and molecular level in schizophrenia are gradually coming to be better understood. Using post mortem material from patients with schizophrenia, Allen et al. (this issue) found reduced neurogenesis in the hippocampus, but importantly, this was unrelated to age, duration of illness or exposure to antipsychotics. Though its sample size was small, this study is one more tile in the expanding mosaic of the neurobiology of psychosis.
In the late 19th century, Henry Maudsley astutely noted that diabetes was often present in the families of persons with psychosis. Certainly, diabetes and schizophrenia occur in the same individual well above chance, but many factors could lead to this comorbidity. Some 130 years later, Foley et al. (this issue) have made commendable use of the Australian National Survey of Psychosis to show that a family history of type 2 diabetes and of schizophrenia do co-occur well above chance, and this is not due to antipsychotic drugs. Importantly, the association was found only in those with individuals who had pure schizophrenia, and not other paranoid or affective psychoses. This is a study using exemplary methodology, a model for postgraduate training and Journal Clubs, because these authors identify and then exclude the many biases and confounders that could mislead a naïve investigator. The recommendations of the National Mental Health Commission have caused much perturbation in Australia. The Commentary by Neil et al. (this issue) spells out that a rational policy cannot be achieved while there is lack of information on key outcomes, outcomes for patients, families and the national exchequer. As with the US invasion of Iraq, the consequences have not been considered. All efforts to progress will remain blind without further research and evaluation.
Are some countries spared the amount of mental illness we have? Mulder et al. (this issue) ask why Samoa really does seem to have a strikingly lower prevalence and less social burden. Their argument is engaging. To tackle the truth of their observation, some hard questions have now to be asked. What would some refutable hypotheses propose? Are the prevalence rates at the population Clinical Guidelines, psychosis and other gripping things level -not the treated prevalence -lower for all mental disorders, or just some, such as depression, schizophrenia, selfharm or substance abuse? But a word of caution: suppose any major group were indeed lower. It would be a challenging and costly task to obtain conclusive evidence, and then explain it. Speculation such as these authors offer would be only the beginning.
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